Purification of human dihydro-orotate dehydrogenase and its inhibition by A77 1726, the active metabolite of leflunomide.

Documenti analoghi

• The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function
  di: Kirsch, Bernhard M, et al.
  Pubblicazione: (2005)
• The active metabolite of leflunomide, A77-1726, increases proliferation of human synovial fibroblasts in presence of IL-1β
  di: Magne, D, et al.
  Pubblicazione: (2004)
• Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1β stimulated rheumatoid synovial fibroblasts
  di: MIGITA, K, et al.
  Pubblicazione: (2004)
• Therapeutic drug monitoring of A77 1726, the active metabolite of leflunomide: serum concentrations predict response to treatment in patients with rheumatoid arthritis
  di: van Roon, E N, et al.
  Pubblicazione: (2005)
• Protein instability and functional defects caused by mutations of dihydro-orotate dehydrogenase in Miller syndrome patients
  di: Fang, JingXian, et al.
  Pubblicazione: (2012)